WAYNE, Pa. and MISGAV, Israel, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of orphan diseases, today released initial positive clinical data from the clinical study of MDGN-201, as well as third quarter financial results.
Management Commentary
“We are excited to provide the initial positive results from the first three patients enrolled in our open-label study of MDGN-201,” stated Mike Cola, Chief Executive Officer of Medgenics.
“The modifications we have undertaken to optimize the platform are translating into clinical results that validate our ex vivo gene therapy approach,” stated Garry Neil, M.D., Chief Scientific Officer of Medgenics. “The platform is delivering sustained, physiologically relevant levels of endogenous erythropoietin (eEPO), which in turn is maintaining hemoglobin within the desired range. Based on these results, we plan on initiating programs in identified orphan populations of unmet need, including end stage renal disease (ESRD) patients who are poorly responsive to recombinant humanized erythropoietin (rHuEPO), and Beta Thalassemia Intermedia patients. We intend to initiate Phase 2 proof of concept clinical trials in both of these indications in 2015. Initial results are expected in the second half of 2015. We are also exploring additional orphan indications for MDGN-201.”
“Additionally, we have developed a novel system for the expression and secretion of small, endogenous peptides,” continued Dr. Neil. “This will enable us to address many orphan disease targets, the first of which is GLP-2 (glucagon-like peptide-2) for short bowel syndrome. We look forward to discussing all of these results during our third quarter conference call and webcast.”
For full article, please click here.
Help employers find you! Check out all the jobs and post your resume.
